Fundraising Fox

Finch Therapeutics

Delaware corporation · 5 known investors

finchtherapeutics.com ↗

Finch is a microbiome therapeutics company that develops innovative microbiome assets designed from human microbiota transplantation studies, targeting a range of therapeutic areas. The company holds a robust intellectual property portfolio in the microbiome field.

BiotechMedical Devicesin /finch-therapeutics@finch_tx

Founders & leadership

RJ
R. J. PriceDirector
JA
Jeffery A. SmisekDirector
MS
Mark SmithExecutive Officer, Director
AM
Andrew MulderryDirector
CL
Chris LangeDirector
JB
James BurgessDirector
AN
Andrew NohDirector
ZK
Zain KassamExecutive Officer
BE
Benjamin EnersonExecutive Officer

Investors · 5

B3 HoldingPrague
Octave Ventures LlcHenderson
OCV PartnersLos Angeles
OMX VenturesLincolnshire
HumboldtreportedNew York · $100K – $5M

Reported raises · per SEC filings

Form D private placements
▶$90MraisedSep 2020 · 43 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Domenic FerranteDirector
  • Jo VineyDirector
  • Zain KassamExecutive Officer
  • Jeffery A. SmisekDirector
  • Mark SmithExecutive Officer, Director
  • Christopher CosmidesDirector
  • Benjamin EnersonExecutive Officer
  • James BurgessExecutive Officer
  • Andrew MulderryDirector
  • Andrew NohExecutive Officer
  • Chris LangeDirector
Offering amount
$90M
Amount sold
$90M
First sale
Sep 2020
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$53.5MraisedJul 2019 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew MulderryDirector
  • Chris LangeDirector
  • Domenic FerranteDirector
  • Jeffery A. SmisekDirector
  • Alan GrossDirector
  • Greg PerryExecutive Officer
  • Ulrich ThienelExecutive Officer
  • Mark SmithExecutive Officer, Director
  • Andrew NohExecutive Officer
  • Benjamin EnersonExecutive Officer
  • Zain KassamExecutive Officer
  • James BurgessExecutive Officer
Offering amount
$53.5M
Amount sold
$53.5M
First sale
May 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$36.4MraisedMar 2018 · 14 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • R. J. PriceDirector
  • Jeffery A. SmisekDirector
  • Mark SmithExecutive Officer, Director
  • Andrew MulderryDirector
  • Chris LangeDirector
  • James BurgessDirector
  • Andrew NohDirector
  • Zain KassamExecutive Officer
  • Benjamin EnersonExecutive Officer
Offering amount
$36.4M
Amount sold
$36.4M
First sale
Feb 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.